Alphabet Inc’s Taysha Gene Therapies TSHA Stock Holding History

Alphabet Inc’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-640,882	Closed	-$2.1M	–	35
2025 Q3	$2.1M	Hold	640,882	–	–	0.09%	25
2025 Q2	$1.48M	Hold	640,882	–	–	0.07%	27
2025 Q1	$891K	Hold	640,882	–	–	0.06%	31
2024 Q4	$1.11M	Hold	640,882	–	–	0.06%	30
2024 Q3	$1.29M	Hold	640,882	–	–	0.07%	31
2024 Q2	$1.44M	Hold	640,882	–	–	0.07%	33
2024 Q1	$1.84M	Hold	640,882	–	–	0.07%	32
2023 Q4	$1.13M	Hold	640,882	–	–	0.05%	36
2023 Q3	$2.03M	Hold	640,882	–	–	0.13%	30
2023 Q2	$423K	Hold	640,882	–	–	0.02%	40
2023 Q1	$513K	Hold	640,882	–	–	0.03%	41
2022 Q4	$1.45M	Hold	640,882	–	–	0.08%	40
2022 Q3	$1.24M	Hold	640,882	–	–	0.06%	42
2022 Q2	$2.38M	Hold	640,882	–	–	0.13%	39
2022 Q1	$4.18M	Hold	640,882	–	–	0.14%	40
2021 Q4	$7.47M	Hold	640,882	–	–	0.18%	38
2021 Q3	$11.9M	Hold	640,882	–	–	0.28%	28
2021 Q2	$13.6M	Hold	640,882	–	–	0.28%	24
2021 Q1	$13M	Hold	640,882	–	–	0.52%	21
2020 Q4	$17M	Hold	640,882	–	–	0.82%	17
2020 Q3	$14.4M	Buy	+640,882	New	+$15.1M	0.67%	11

Other funds holding TSHA

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Alphabet Inc's TSHA Position: Q4 2025 in Review

Alphabet Inc sold out of Taysha Gene Therapies (TSHA) in Q4 2025, closing a stake of 640,882 shares — an estimated $2.1M sold.

Alphabet Inc first reported a position in TSHA in Q3 2020 and held it in 21 quarters. The position peaked at $17M in Q4 2020. 195 funds tracked by Wall St. Rank hold TSHA as of Q4 2025.

Alphabet Inc reported no remaining Taysha Gene Therapies position as of Q4 2025 after selling out during the quarter.
Alphabet Inc sold 640,882 Taysha Gene Therapies shares in Q4 2025, an estimated $2.1M.
Alphabet Inc first reported a position in Taysha Gene Therapies in Q3 2020 and held it in 21 quarters.
Alphabet Inc's Taysha Gene Therapies position peaked at $17M in Q4 2020.
195 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q4 2025.

Based on Alphabet Inc's 13F filing for Q4 2025, filed 13 Feb 2026.